Hansoh Pharma (03692): The application for the marketing authorization of HS-10365 capsules has been accepted by the National Medical Products Administration.
Hanson Pharmaceuticals (03692) announced on October 23, 2025 that the group has successfully developed a highly selective transfection reagent for innovative drugs...
Hansoh Pharma (03692) announced that on October 23, 2025, the group's new drug, a highly selective transduction rearrangement inhibitor capsule HS-10365, has received acceptance for market approval application (NDA) from the National Medical Products Administration (NMPA) of China. This drug is intended for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with RET gene fusion positivity.
Related Articles
US Stock Market Move | STMicroelectronics NV ADR RegS (STM.US) fell over 12% with Q3 operating profit below expectations.
IMAX CHINA (01970): IMAX Corporation's net profit attributable to shareholders in the first three quarters increased by 64.98% to $34.239 million.
US Stock Market Move | Popular Chinese concept stocks are generally up. Baidu Inc Sponsored ADR Class A(BIDU.US) rose more than 3%.
US Stock Market Move | STMicroelectronics NV ADR RegS (STM.US) fell over 12% with Q3 operating profit below expectations.
IMAX CHINA (01970): IMAX Corporation's net profit attributable to shareholders in the first three quarters increased by 64.98% to $34.239 million.
US Stock Market Move | Popular Chinese concept stocks are generally up. Baidu Inc Sponsored ADR Class A(BIDU.US) rose more than 3%.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
